Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...
Santa Monica, California Thursday, November 7, 2024, 10:00 Hrs [IST] ...
Two poster presentations to feature novel data from the Phase 1/2 SIDNEY trial of EO2463 in indolent Non-Hodgkin Lymphoma (iNHL), highlighting initial data from Cohort 2 as monoth ...
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ...
来自MSN22 小时
国内首款！博安生物靶向CD228的创新ADC药物获批开展临床试验公司的新药发现活动围绕多个平台展开，包括全人抗体转基因小鼠及噬菌体展示技术平台、双特异T-cell Engager技术平台、抗体药物偶联（ADC）技术平台及细胞治疗平台。 博安生物拥有完整的涵盖抗体发现、细胞株开发、上游及下游工艺开发、分析及生物分析方法 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈